NU-SERTRALINE CAPSULES

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

SERTRALINE (SERTRALINE HYDROCHLORIDE)

Commercializzato da:

NU-PHARM INC

Codice ATC:

N06AB06

INN (Nome Internazionale):

SERTRALINE

Dosaggio:

100MG

Forma farmaceutica:

CAPSULE

Composizione:

SERTRALINE (SERTRALINE HYDROCHLORIDE) 100MG

Via di somministrazione:

ORAL

Confezione:

100

Tipo di ricetta:

Prescription

Area terapeutica:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Dettagli prodotto:

Active ingredient group (AIG) number: 0123417002; AHFS:

Stato dell'autorizzazione:

CANCELLED POST MARKET

Data dell'autorizzazione:

2012-09-04

Scheda tecnica

0
PRODUCT MONOGRAPH
NU-SERTRALINE
Sertraline Hydrochloride Capsules
Equivalent to 25, 50 and 100 mg Sertraline
Antidepressant / Antipanic / Antiobsessional Agent
NU-PHARM INC.
DATE OF PREPARATION:
50 Mural Street, Units 1 & 2
January 2, 2003
Richmond Hill, Ontario
DATE OF REVISION:
L4B 1E4 July 28, 2005
_Control # 096152_
1
PRODUCT MONOGRAPH
NU-SERTRALINE
Sertraline Hydrochloride Capsules
Equivalent to 25, 50 and 100 mg
THERAPEUTIC CLASSIFICATION
Antidepressant – Antipanic – Antiobsessional Agent
ACTIONS AND CLINICAL PHARMACOLOGY
The mechanism of action of sertraline is presumed to be linked to its
ability to inhibit the neuronal
reuptake of serotonin. It has only very weak effects on norepinephrine
and dopamine neuronal
reuptake. At clinical doses, sertraline blocks the uptake of serotonin
into human platelets.
Like most clinically effective antidepressants, sertraline
down–regulates brain norepinephrine and
serotonin receptors in animals. In receptor binding studies,
sertraline has no significant affinity for
adrenergic (_alpha_
_1_
_, alpha_
_2_
_ & beta_), cholinergic, GABA, dopaminergic, histaminergic,
serotonergic
(5–HT1A, 5–HT1B, 5–HT2) or benzodiazepine binding sites.
In placebo–controlled studies in normal volunteers, sertraline did
not cause sedation and did not
interfere with psychomotor performance.
Pharmacokinetics:
Following multiple oral once-daily doses of 200 mg, the mean peak
plasma concentration (C
max
)
of sertraline is 0.19
:
g/mL occurring between 6 to 8 hours post-dose. The area under the
plasma
concentration time curve is 2.8 mg
q
hr/L. For desmethylsertraline, C
max
is 0.14
:
g/mL, the half-life
65 hours and the area under the curve 2.3 mg
q
hr/L. Following single or multiple oral once-daily
2
doses of 50 to 400 mg/day the average terminal elimination half-life
is approximately 26 hours.
Linear dose proportionality has been demonstrated over the clinical
dose range of 50 to
200 mg/day.
Food appears to increase the bioavailability by about 40%; it is
recommended that NU-
SERT